Timothy M Illidge

14PUBLICATIONS
36CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursMedical mycologyPredictive and prognostic markersImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Feb 27, 2026
A Phase II Study of <sup>177</sup>Lu-Lilotomab Satetraxetan, a CD37 Antibody-Radionuclide Conjugate, as Third- or Later-Line Treatment of Rituximab-Refractory Follicular B-Cell Lymphoma Patients.

Roy H Larsen, Arne Kolstad, Alexander Fosså

|Jan 08, 2025
Maximum tumor diameter is associated with relapse risk in limited-stage Hodgkin lymphoma: an international study.

Elizabeth H Phillips, Nicholas Counsell, Tim Illidge

|Dec 09, 2023
A Retrospective Chart Review of Treatment Patterns and Overall Survival among a Cohort of Patients with Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom.

Chalid Assaf, Timothy M Illidge, Nathalie Waser

|May 27, 2023
Hypoxia Is Associated with Increased Immune Infiltrates and Both Anti-Tumour and Immune Suppressive Signalling in Muscle-Invasive Bladder Cancer.

Vicky Smith, Dave Lee, Mark Reardon

|Jan 08, 2023
Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.

Vicky Smith, Debayan Mukherjee, Anna Maria Tsakiroglou

|Apr 06, 2022
Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.

James M Price, Hitesh B Mistry, Guy Betts

Pageof 3

Frequent Collaborators

3 joint publications

Peter J Hoskin

2 joint publications

John Radford

2 joint publications

Elizabeth H Phillips

1 joint publications

S J Whittaker